In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Niraparib is under clinical development by GSK and currently in Phase II for Cervical Cancer ... role in drug-specific PTSR and likelihood of approval. Niraparib (MK-4827, Zejula) is an ...

GSK is also working on expanding the label of marketed products like Nucala, Zejula and Jemperli into additional indications.

GSK has continued to beat my expectations as ... The company's oncology portfolio, consisting of Zejula, Blenrep, Jemperli, and Ojjaara/Omjjara, reported total sales of $450 million in the second ...

GSK has a strong portfolio of marketed drugs for oncology indications, including Jemperli (dostarlimab), Zejula (niraparib) and Ojjaara, which are approved for various cancer indications.

GSK reported adjusted earnings of 72 cents per ... registered impressive growth on the back of rising Jemperli and Zejula sales and the newly-launched Ojjaara. Sales in the United States rose ...

study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC. The study is being conducted in partnership with ...

The phase I/II MAMMOTH (ZN-c3-006) study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC.